Abstract
Thyroid cancer (TC) is a significant global healthcare burden. However, the lack of comprehensive data has impeded our understanding of its global impact. We aimed to examine the burden of TC and its trends at the global, regional, and national levels using data stratified by sociodemographic index (SDI), sex, and age. Data on TC, including incidence, mortality, and disability-adjusted life-years (DALYs) from 1990 to 2021, were obtained from the Global Burden of Disease Study 2021. Estimated annual percentage changes (EAPCs) were calculated to assess the incidence rate, mortality, and DALYs trends. The incidence, mortality, and DALYs of TC in 2021 were 249,538 (95% uncertainty interval: 223,290-274,638), 44,799 (39,925-48,541), and 646,741 (599,119-717,357), respectively. The age-standardized incidence rate (ASIR) in 2021 was 2.914 (2.607-3.213), with an EAPC of 1.25 (1.14-1.37) compared to 1990. In 2021, the age-standardized death rate (ASDR) was 0.53 (0.47-0.575) and age-standardized DALYs rate was 14.571 (12.783-16.115). Compared with 1990, the EAPCs of ASDR and age-standardized DALYs rate showed decreasing trends, at - 0.24 (- 0.27 to - 0.21) and - 0.14 (- 0.17 to - 0.11), respectively. Low SDI regions showed the highest ASDR and age-standardized DALYs rate, at 0.642 (0.516-0.799) and 17.976 (14.18-23.06), respectively. Low-middle SDI regions had the highest EAPCs for ASDR and age-standardized DALYs rate, at 0.74 (0.71-0.78) and 0.67 (0.63-0.7), respectively. Females exhibited decreasing trend in ASDR and age-standardized DALYs rate, with EAPCs of - 0.58 (- 0.61 to - 0.55) and - 0.45 (- 0.47 to - 0.42), respectively. In contrast, males showed an increasing trend in ASDR and age-standardized DALYs rate, with EAPCs of 0.41 (0.35-0.46) for both. Over the past few decades, a notable increase in TC incidence and decreased mortality has been observed globally. Regions characterized by lower SDI, male sex, and an aging population exhibited no improvement in TC mortality. Effective resource allocation, meticulous control of risk factors, and tailored interventions are crucial for addressing these issues.
Introduction
Thyroid cancer (TC) is the most common endocrine malignancy, yet its global impact has historically been difficult to quantify due to fragmented data. This study provides a comprehensive 30-year systematic analysis of the global TC burden using the Global Burden of Disease (GBD) Study 2021 framework. By examining incidence, mortality, and disability-adjusted life-years (DALYs) across 204 countries, the researchers highlight critical trends stratified by age, sex, and sociodemographic status. The findings reveal a significant paradox: while global incidence is climbing, overall mortality is declining, though this progress remains unevenly distributed.
Global Trends and Sociodemographic Disparities
The global landscape of thyroid cancer is characterized by a rising incidence rate (ASIR EAPC 1.25) alongside a modest decrease in the age-standardized death rate (ASDR EAPC -0.24). However, these global averages mask significant disparities linked to the Sociodemographic Index (SDI).
As illustrated in Figure 6, high-SDI regions report the highest incidence rates, likely reflecting a "screening effect" where advanced diagnostics identify small, asymptomatic tumors. In contrast, low-SDI regions suffer from the highest mortality rates (ASDR 0.642), suggesting that TC is often detected at more advanced stages. Alarmingly, low-middle SDI regions have seen the fastest increase in death rates, indicating a growing healthcare gap.
Geographic and Demographic Divergence
The geographic distribution of the TC burden reveals specific areas of concern, particularly in regions where mortality rates are not following the global downward trend.
Figure 5 maps these variations, showing that while many nations have reduced their TC death rates, others in Africa and Asia face rising burdens. Demographically, the study identifies a concerning "male mortality divergence." While TC is twice as common in females, female mortality is decreasing (EAPC -0.58), whereas male mortality is increasing (EAPC 0.41). This suggests that males may be underserved by current screening programs or present with more aggressive disease subtypes. Furthermore, as the global population ages, the burden in older age groups (peaking at 55–59 years) is becoming increasingly prominent, particularly in high-income countries.
Conclusion
The systematic analysis of GBD 2021 data underscores the evolving nature of the global thyroid cancer burden. While medical advancements have improved overall survival, the rising incidence and the specific vulnerabilities of males, aging populations, and low-SDI regions require urgent attention. Future efforts must focus on identifying sex-specific risk factors and implementing tailored screening and treatment strategies for high-risk demographics and underserved regions.
Summary updated